600867.SH
通化东宝
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 7.95
−1.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0B | 2.9B | 2.0B | 3.1B | 2.8B |
| Cost of Revenue | 886.8M | 874.5M | 524.5M | 612.8M | 617.5M |
| Gross Profit | 2.2B | 2.1B | 1.5B | 2.5B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | 165.3M | 167.1M | 99.3M | 105.0M | 146.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 177.2M | 180.9M | 182.6M | 134.5M | 180.6M |
| Selling & Marketing Expense | 1.1B | 1.1B | 1.1B | 912.8M | 933.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.5B | 1.5B | 1.4B | 1.2B | 1.3B |
| Cost and Expenses | 2.4B | 2.4B | 1.9B | 1.8B | 1.9B |
| Operating Income (EBIT) | 1.6B | 1.6B | 169.7M | 1.4B | 1.8B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.5B | 1.5B | (142.3M) | 1.4B | 1.8B |
| Income Tax Expense | 317.5M | 280.1M | (99.6M) | 198.0M | 247.7M |
| Bottom Line | |||||
| Net Income | 1.2B | 1.2B | (42.0M) | 1.2B | 1.6B |
| Earnings from Cont. Ops | 1.2B | 1.2B | (42.5M) | 1.2B | 1.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 1.2B | (42.0M) | 1.2B | 1.6B |
| Per Share | |||||
| Basic EPS | CN¥0.62 | CN¥0.62 | (CN¥0.02) | CN¥0.59 | CN¥0.79 |
| Diluted EPS | CN¥0.62 | CN¥0.62 | (CN¥0.02) | CN¥0.59 | CN¥0.79 |
| Revenue Per Share | CN¥1.44 | CN¥1.50 | CN¥0.96 | CN¥1.55 | CN¥1.39 |
| Shares | |||||
| Basic Shares Outstanding | 2.1B | 2.0B | 2.1B | 2.0B | 2.0B |
| Diluted Shares Outstanding | 2.1B | 2.0B | 2.1B | 2.0B | 2.0B |
| Profitability Metrics | |||||
| EBITDA | — | 1.9B | 373.5M | 1.6B | 2.0B |
| D&A | — | 293.7M | 203.8M | 185.3M | 133.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026